Bayer Considers Halting Glyphosate Production, Citing Unsustainable Litigation Burden
-
Bayer CEO Bill Anderson stated that the company is considering withdrawing Roundup from the U.S. market due to escalating legal costs linked to cancer-related lawsuits.
-
Glyphosate, the active ingredient in Roundup, represents a significant share of global herbicide use; Bayer currently accounts for around 40% of global supply.
-
A production halt could shift glyphosate sourcing heavily towards China, which already dominates global export volumes for the product.
-
Legal liabilities tied to Roundup have cost Bayer more than USD 10 billion and continue to pressure the company’s profitability and stock performance.
-
Bayer is lobbying U.S. state legislatures to introduce legal protections and is appealing to the U.S. Supreme Court to address conflicting rulings across state and federal levels.
-
Cities like St. Louis, Missouri — historically linked with Monsanto — have become focal points for litigation, reflecting the growing complexity of herbicide regulation in the U.S.
Industry and Market Insight:
Glyphosate has long been the backbone of modern herbicide regimes, especially in row crop systems reliant on genetically modified organisms (GMOs). However, persistent litigation in the U.S. has become a major cost center for Bayer since acquiring Monsanto in 2018.
CEO Bill Anderson has emphasized that litigation losses from Roundup now outweigh Bayer’s entire agriculture R&D budget in some years. “We barely break even on glyphosate,” Anderson noted, estimating annual losses of up to USD 3 billion when litigation costs are considered. Despite generating USD 2.8 billion in glyphosate sales in 2024, the company faces financial strain as legal verdicts mount.
City Focus – St. Louis, Missouri:
St. Louis, the former headquarters of Monsanto, has played a central role in glyphosate litigation. In a recent case, a Missouri court awarded USD 1.25 million to a man who developed non-Hodgkin’s lymphoma after using Roundup. This location has symbolic and legal relevance in the ongoing legal battles, drawing attention to the challenges agrochemical giants face in balancing public health concerns with regulatory compliance.
Shift Towards Chinese Suppliers:
If Bayer exits glyphosate production, U.S. farmers would become more reliant on Chinese manufacturers, including key players in Shandong and Jiangsu. Chinese producers have expanded glyphosate capacity in recent years, with stable export pricing and favorable domestic raw material availability. According to China Informatics, the March 2024 FOB Shanghai price for 95% glyphosate TC was USD 3,602/t, indicating competitive international supply.
The policy shift could inadvertently increase U.S. dependence on Chinese agrochemical inputs, reinforcing China’s status as the global production hub for glyphosate. Meanwhile, environmental scrutiny around glyphosate remains a sensitive topic in both Western and Chinese markets.
Company Dynamics and Future Outlook:
Bayer is actively lobbying U.S. states such as Georgia and North Dakota, where pesticide labeling reforms have recently passed. The company is also urging the Supreme Court to revisit federal preemption principles, arguing that federal EPA-approved labels should shield companies from state-level failure-to-warn lawsuits.
A decision to cease glyphosate production would mark a strategic pivot for Bayer’s crop science division, signaling a deeper focus on next-generation herbicides and biologics — but also a potential loss of a flagship product that once defined Monsanto’s agrochemical legacy.
